Docetaxel-Based Chemotherapy with Zoledronic Acid and Prednisone in Hormone Refractory Prostate Cancer: Factors Predicting Response and Survival

We know that docetaxel chemotherapy (chemo) extends life, but which men might hope to experience an increase in survival? The Department of Urology, All India Institute of Medical Sciences, New Delhi, India performed a small study designed to evaluate the efficacy of docetaxel/prednisone and zoledronic acid in the treatment of men with hormone refractory prostate [...]

The Survival Implications of Bone Mineral Loss

In a Town Hall discussion,  “Ablating Testosterone in Prostate Cancer and the Concomitant Negative Effects”,  Fred Saad, MD,  FRCS, Director of Urologic Oncology, Professor of Surgery/Urology, U of M Chair in Prostate Cancer; University of Montreal discussed the negative effects that bone loss resulting from hormone therapy (ADT)  poses to our life expectancy. His over [...]

Stereotactic Radio Surgery (SRS) Successfully Treats Pain in Patients with Advanced Cancer that has Spread to Bones

According to researchers from University of Pittsburgh Cancer Institute (UPCI), Stereotactic Radio Surgery (SRS), which was developed at UPCI, can successfully control pain in patients with cancer that has spread to the spine. SRS is a procedure that precisely delivers a large dose of radiation directly to tumors. The researchers from UPCI, led by Dwight [...]

On the Horizon – A Quick Summary of the Status of Some of the Up Coming Treatments for Advanced Prostate Cancer

Provenge, a cancer vaccine, has demonstrated its ability to improve the survival of men with castrate resistant prostate cancer (CRPC). The developer, Dendreon, has submitted it latest clinical trial data to the FDA for approval. We hope to have an approval by mid-year 2010. Growth factors were thought to be potential targets for treating prostate [...]

Rapid PSA Decline After Docetaxel Chemotherapy is Associated with Improved Survival in Hormone Refractory Prostate Cancer

A chart review performed at the Department of Internal Medicine, University of Alberta, Edmonton, AB. concluded that the a quick rate of initial PSA decline in men with hormone refractory prostate cancer receiving docetaxel chemotherapy (chemo) predicts an increased overall survival (OS). Studies have demonstrated that docetaxel chemotherapy does prolong survival in metastatic hormone-refractory prostate [...]

Go to Top